Click on the titles to view more details of each session.
Click on the titles to view more details of each session.
Click on the titles to view more details of each session.
Click on the titles to view more details of each session.
| Day 4 (Sunday) – 19 November 2023 | |||||||||
| Time | Scientific Programme | ||||||||
| Esplanade Hall – 406CX | |||||||||
| 08:00 – 08:30 |
Invited Lecture 2 Prof. Judith Garcia-Aymerich (ERS Secretary General) |
||||||||
| 08:30 – 09:00 |
Invited Lecture 3 Dr. Toyohiro Hirai (JRS Chairman of the Board of Directors) |
||||||||
| Level 4 | Level 3 | Level 4 | |||||||
| Esplanade Hall 406CX |
Sentosa Hall 404A |
Orchard Hall 405B |
Changi Hall 406D |
Room – 332 | Room – 336 | Room – 334 | Room – 335 | Hall – 403 | |
| 09:30 – 11:00 |
APSR GOLD Joint Session | Symposium 34 | Symposium 35 | Symposium 36 | Symposium 37 | Oral Session 29 | Oral Session 30 | Oral Session 31 | |
| Respiratory Infections (Non-TB) 3 | Asthma 4 | Clinical Allergy and Immunology 2 | Lung Cancer 3 | COPD 3 | Clinical Respiratory Medicine 4 | Bronchoscopy and Interventional Techniques 2 | |||
| 11:00 – 11:20 |
Break | Break | Break | Break | Break | Break | Break | Break | |
| 11:20 – 12:50 |
Symposium 38 | Symposium 39 | Symposium 40 | Symposium 41 | Young Investigator Award 2 | Oral Session 32 | Poster Session 9 | ||
| COPD 4 | Tuberculosis 2 | Critical Care Medicine 3 | Respiratory Structure and Function 2 | Respiratory Infections (Non-TB) 4 | |||||
| 12:50 – 13:20 |
Level 4, Esplanade Hall, 406CX Closing Ceremony |
||||||||
Programme is updated as of 17 November 2023.
The APSR Singapore Congress Scientific Committee reserves the right to modify the program, which is published as an indication only.
The opinions expressed within the Sponsored Satellite Symposia are solely the speakers’ and do not reflect the opinions and beliefs of APSR.
Pre-Congress Workshop 1
| 09:00 – 12:00
Pre-Congress Workshop 1 (Asthma) |
| 09:00 – 09:30
Approach to difficult asthma |
| 09:30 – 10:00
How we do it – setting up a severe asthma service |
| 10:00 – 10:30
Overview on asthma biologics |
| 10:30 – 11:00
Assessing biologic response |
| 11:00 – 12:00
Case Discussions |
Pre-Congress Workshop 2
| 09:00 – 12:00
Pre-Congress Workshop 2 (Bronchoscopy and Interventional Techniques) |
| 08:00 – 08:30
Rigid Bronchoscopy, Stenting, Dilatation |
| 08:30 – 09:00
Cases to Illustrate Techniques to Relieve Central Airway Obstruction |
| 09:00 – 09:30
EBUS,EUS or Mediastinoscopy for Mediastinal Staging |
| 09:30 – 10:00
Transbronchial Cryobiopsy for ILD, Lung Infiltrates and Mediastinal Masses |
| 10:00 – 10:30
Break |
| 10:30 – 11:10
Targeting the Pulmonary Nodule: Pro and Con of Navigational Systems, Cone Beam CT, and Robotic Bronchoscopy |
| 11:10 – 11:30
Factors Affecting Diagnostic Yield in Bronchoscopic Samples – A Pathologist’s Perspective |
| 11:30 – 11:50
Procedure for Rare Disease: Whole Lung Lavage vs Sequential Lobar Lavage for Pulmonary Alveolar Proteinosis: Indicators, Complications and Technical Know-How |
| 11:50 – 12:10
Thorascopic Talc Pleurodesis or IPC for Malignant Pleural Effusion |
Pre-Congress Workshop 3
| 09:00 – 12:00
Pre-Congress Workshop 3 (Respiratory Neurobiology and Sleep) |
| 08:30 – 09:45
CPAP – Mask Fitting and Devices with Hands-on |
| 10:00 – 10:30
Inspire Hypoglossal Nerve Stimulation (HGN) – Setup, titration, and troubleshooting |
| 10:30 – 11:00
CBTi Psychology and CPAP Adherence |
| 11:00 – 11:15
Break |
| 11:15 – 12:00
Orofacial Myofunctional Therapy (OMFT) |
Pre-Congress Workshop 4
| 09:00 – 12:00
Pre-Congress Workshop 4 (Interstitial Lung Disease) |
| Diagnostic approach to ILD Prof. Athol Wells (UK) How to interpret HRCT chest of ILD How to interpret lung function tests in ILD How to interpret autoimmune serologies in ILD How to manage ILD How to set up an ILD service |
Pre-Congress Workshop 5
| 09:00 – 12:00
Pre-Congress Workshop 5 (Tuberculosis) |
| 09:00 – 10:00
Case-Based Discussion |
| 10:00 – 11:00
Case-Based Discussion |
| 11:00 – 12:00
Case-Based Discussion |
Pre-Congress Workshop 6
| 14:00 – 17:00
Pre-Congress Workshop 6 (Clinical Respiratory Medicine) |
| Pearls in Chest Radiology Radiation Safety Interesting Chest X-rays CT Techniques and Applications Interesting CTs Future of Chest Radiology |
Pre-Congress Workshop 7
| 13:45 – 17:00
Pre-Congress Workshop 7 (Clinical Respiratory Medicine) |
| Hands-on Stations: 8 Stations
EBUS TBNA With New Flex Scope 19G/22G Needles EBUS Radial Probe: Nurses Training Robotic Bronchoscopy: Plan, Target, Bx Cryostation: Disposable Scope With Cryoprobe +/- Sheath Plus Blocker FB/ Clot Removal With Cryotherapy Flex-Rigid Pleuroscopy Station Rigid Bronch With Silicone Stent Metal Stent With Flexible Bronchoscopy Ask the Pathologist |
Pre-Congress Workshop 8
| 14:00 – 17:00
Pre-Congress Workshop 8 (Paediatric Lung Disease) |
| 14:00 – 15:00
Lung function tests and lung clearance techniques |
| 15:00 – 16:00
CPAP/BiPAP with different interfaces |
| 16:00 – 17:00
PSG/oximetry |
Pre-Congress Workshop 9
| 14:00 – 17:00
Pre-Congress Workshop 9 (Pulmonary Circulation) |
| 14:00 – 14:25
Updates in ESC/ERS 2022 Guidelines for Pulmonary Hypertension |
| 14:25 – 14:50
Pulmonary endarterectomy for CTEPH – Considerations and Challenges |
| 14:50 – 15:15
Challenging Case Discussions |
| 15:15 – 15:30
Break |
| 15:30 – 15:55
Updates in Anticoagulation in Pulmonary embolism |
| 15:55 – 16:20
Catheter direct therapy for intermediate risk PE |
| 16:20 – 16:45
How I manage Intermediate and High Risk Pulmonary Embolism |
| 16:45 – 17:00
Conclusion |
Closing Ceremony
Closing Remarks
| 12:50 – 12:55 | Closing Video of APSR 2023, Singapore |
| 12:55 – 13:00 | Closing Remarks by Dr. Albert Lim, APSR Congress President |
| 13:00 – 13:05 | Closing Remarks by Dr. David C L Lam, APSR President |
| 13:05 – 13:10 | Handover Ceremony to APSR 2024, Hong Kong Dr. Albert Lim, APSR 2023 Congress President Dr. Fanny Ko & Dr. James Ho, APSR 2024 Congress President |
| 13:10 – 13:15 | Promotional Video of APSR 2024, Hong Kong |
Gala Dinner
| 18:30 – 19:30 | Cocktail Reception at Jubilee Ballroom Performance by Dr. Stephanie Yeap |
| 19:35 Onwards | Dinner |
| 19:35 – 19:40 | Opening Remark by Dr. Albert Lim Yick Hou, APSR Congress President |
| 19:40 – 19:45 | Welcome Speech by Dr. David C L Lam, APSR President |
| 19:45 – 20:00 | Light Art Performance by Lawrence Koh |
| 20:00 – 20:45 | Awards Ceremony |
| 20:45 – 20:55 | Unity of Diversity, Ethnic Dance Performance by Sri Warisan |
| 21:00 | Announcement of Lucky Draw Networking Session |
Opening Ceremony & Welcome Reception
| 18:00 – 18:10 | Opening Lion Dance Performance |
| 18:10 – 18:25 | Introduction A/Prof. Albert Lim, APSR Congress President Dr. David C L Lam, APSR President Dr. Chul-Gyu Yoo, APSR President-Elect Dr. Kazuhiro Yatera, Chairperson, APSR Central Congress Committee Dr. Patricia Rivera [ATS], Dr. Monika Gappa [ERS], President of Sister Societies Honorary Guests |
| 18:25 – 18:30 | Welcome speech by A/Prof. Albert Lim, APSR Congress President |
| 18:30 – 18:45 | Opening Remarks Dr. David C L Lam, APSR President Dr. Patricia Rivera [ATS], Dr. Monika Gappa [ERS], President of Sister Societies |
| 18:45 – 18:50 | Welcome Message by Guest of Honour Dr. Chee Yam Cheng, President, The Singapore Medical Council |
| 18:50 – 19:05 | Awards Ceremony APSR Medal Michiyoshi Harasawa Research Award (Annoucenment) Ann Janet Woolcock Research Award (Annoucement) |
| 19:05 – 20:30 | Dinner Reception in Hall 406CX Performance by ShiLi and Adi |
8 Assembly Members’ Meetings with Education Award Sessions
17th November 2023
17:30 – 19:00
| Room No | Assembly | |
| Level 3 | Room 324 | Cell and Molecular Biology |
| Room 325 | Clinical Respiratory Medicine | |
| Room 326 | COPD | |
| Room 327 | Tuberculosis | |
| Room 328 | Asthma | |
| Room 329 | Environmental and Occupational Health & Epidemiology | |
| Level 4 | Hall 403 Meeting Room 1 | Paediatric Lung Disease |
| Hall 403 Meeting Room 2 | Critical Care Medicine |
8 Assembly Members’ Meetings with Education Award Sessions
18th November 2023
17:30 – 19:00
| Room No | Assembly | |
| Level 3 | Room 303 | Respiratory Infections (non-tuberculous) |
| Room 304 | Clinical Allergy & Immunology | |
| Room 308 | Respiratory Neurobiology and Sleep | |
| Room 309 | Respiratory Structure and Function | |
| Room 310 | Pulmonary Circulation | |
| Room 324 | Interstitial Lung Disease | |
| Room 325 | Bronchoscopy and Interventional Techniques | |
| Room 326 | Lung Cancer | |
Memorial Lecture 2
| Memorial Lecture 2
|
[Ann Janet Woolcock] Macrolides and Airways Disease – Bench to BedsideMemorial Lecture 1
| Memorial Lecture 1
|
[Michiyoshi Harasawa] New Strategies to Realize Clinical Remission in AsthmaYoung Investigator Award 1
| 15:20 – 16:50
Young Investigator Award 1 |
| YIA01 – 1
Profiling markers of silicosis in a Victorian cohort of engineered stone workers |
| YIA01 – 2
Association between triglyceride-glucose index and the risk of asthma exacerbation: a prospective cohort study |
| YIA01 – 3
Developing and Validating Prediction Models for Severe Exacerbations and Readmissions in Patients Hospitalized for COPD Exacerbation (SERCO) in China: a Prospective Observational Study |
| YIA01 – 4
Short-term ambient fine particulate matter exposure and peripheral leukocyte count and classification: results from the population-based cohort study in China |
| YIA01 – 5
Novel inhale treatment of IgY immunoglobulin combination with macrocyclic peptide eliminate multidrug-resistant Pseudomonas aeruginosa pulmonary infections |
| YIA01 – 6
Role of Serum Decoy Receptor 3 as a Predictor of Prognosis in Patients with Acute Exacerbation of Interstitial Pneumonia |
| YIA01 – 7
Immune checkpoint inhibitors-related pneumonitis in lung cancer with Interstitial pneumonia: a multicenter retrospective study in Japan |
Young Investigator Award 2
| 11:20 – 12:50
Young Investigator Award 2 |
| 11:20 – 11:30
YIA02 – 1 The Association between PEEP-related Driving Pressure Changes and Mortality in Patients with Moderate-Severe ARDS |
| 11:30 – 11:40
YIA02 – 2 Complex epithelial-fibroblast-ECM interactions assessed via biomimetic lung models and the link between inflammatory and fibrotic disease mechanisms in asthma and COPD |
| 11:40 – 11:50
YIA02 – 3 The secretome of pulmonary microvascular endothelial cells supports alveolar epithelial growth |
| 11:50 – 12:00
YIA02 – 4 Evaluating eligibility for pneumonectomy in patients with bronchial stenosis and atelectasis after pulmonary tuberculosis using cardiopulmonary exercise testing |
| 12:00 – 12:10
YIA02 – 5 Airway epithelial barrier dysfunction in survivors of very preterm birth |
| 12:10 – 12:20
YIA02 – 6 Early tapering of corticosteroid in patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective multi-center cohort study |
Joint Session AJRCCM/Respirology: Advice for Authors
| 13:30 – 15:00 Dialogue with the AJRCCM and Respiratory Editors: What Authors Need to Know? |
| Chairs: A/Prof. Sanjay H. Chotirmall (Singapore) Dr. Laurent Brochard (Canada) Prof. Philip Bardin (Australia) Prof. Paul Reynolds (Australia) |
| 13:30 – 13: 35
Opening Remarks by Chairs |
| 13:35 – 13:55
|
| 13:55 – 14:15
|
| 14:15 – 14:35
|
| 14:35 -14:55
|
| 14:55 – 15:00
Closing Remarks by Chairs |
APSR GOLD Joint Session
| 09:30 – 11:00
APSR GOLD Joint Session |
09:30 – 09:35 Welcome & IntroductionDr. Huiying Xu (Singapore) |
09:35 – 10:00 GOLD 2024 UpdateProf. David MG Halpin (United Kingdom) |
10:00 – 10:15 Current thinking on Pre-COPD and PRISMProf. Fernando J. Martinez (USA) |
10:15 – 10:30 Update on Non-smoking COPDDr. Sundeep Salvi (India) |
10:30 – 10:45 Overcoming the Challenges of Implementing the GOLD Strategy in AsiaAdj A/Prof. Augustine Tee (Singapore) |
| 10:45 – 11:00
Panel Discussion |
Presidential Lecture 1
| 08:00 – 08:30
Presidential Lecture 1 |
 Research on Lung Cancer – The Quest for Knowledge in the Asian Pacific RegionsDr. David Chi-Leung Lam (APSR President, Hong Kong) |
Presidential Lecture 2
| 08:30 – 09:00
Presidential Lecture 2 |
 Mycobacterium Abscessus Pulmonary Disease- Current Challenges and Future HopeA/Prof. Albert Yick Hou Lim (STS President, Singapore) |
Keynote Lecture 1
| 08:00 – 08:30
Keynote Lecture 1 |
 Lung Cancer in Women: A Veiled EpidemicDr. M. Patricia Rivera (ATS President, USA) |
Invited Lecture 1
| 08:30 – 09:00
Invited Lecture 1
Prof. Monika Gappa (ERS President)
|
Early Childhood and Lifelong Lung Health – Opportunities for Prevention
Prof. Monika Gappa (ERS President, Germany)
|
Invited Lecture 2
| 08:00 – 08:30
Invited Lecture 2
Prof. Judith Garcia-Aymerich (ERS Secretary General)
|
Physical Activity in COPD
Prof. Judith Garcia-Aymerich (ERS Secretary General, Spain)
|
Invited Lecture 3
| 08:30 – 09:00
Invited Lecture 3
Dr. Toyohiro Hirai (JRS Chairman of the Board of Directors)
|
Advances in Chest Image Analysis of Respiratory Disease
Prof. Toyohiro Hirai (JRS Chairman of the Board of Directors, Japan) |
Symposium 1
| 09:00 – 10:30
COPD 1 |
09:00 – 09:30 Early-Life Determinants of COPD: Can We Intervene EarlierProf. Fernando J. Martinez (USA) |
09:30 – 10:00 Advancement on CT Analysis of COPDProf. Yasutaka Nakano (Japan) |
10:00 – 10:30 Advancing COPD Care and Big Data AnalyticsProf. Chin Kook Rhee (Republic of Korea) |
Symposium 2
| 09:00 – 10:30
Tuberculosis 1 |
09:00 – 09:20 Defining the Spectrum of TB Infection to Disease, and Implications for Clinical ManagementDr. Chi Chiu Leung (Hong Kong) |
09:20 – 09:40 Update on Rapid Molecular Tests for TB DiagnosisDr. Li-Hwei Sng (Singapore) |
09:40 – 10:00 Active TB Drug Safety Monitoring and Management – Taiwan ExperienceDr. Rebecca Chou-Jui Lin (Taiwan) |
10:00 – 10:20 WHO Strategy End TB Strategy – Will Its Targets Be Achieved by 2035?Prof. Charles L. Daley (USA) |
| 10:20 – 10:30
Q&A |
Symposium 3
| 09:00 – 10:30
Lung Cancer 1 |
09:00 – 09:30 Lung Cancer Screening in Never Smokers: Insights From the TALENT StudyProf. Pan-Chyr Yang (Taiwan) |
| 09:30 – 10:00Lung Cancer Screening in Smokers – COLD or GOLD? Dr. M. Patricia Riveria (USA) |
10:00 – 10:30 Considerations for a Lung Cancer Screening Program in SingaporeDr. Gillianne Lai (Singapore) |
Symposium 4
| 09:00 – 10:30
Critical Care Medicine 1 |
09:00 – 09:30 ARDS SubphenotypingAsst Prof. Pratik Sinha (USA) |
09:30 – 10:00 Prone Positioning – How Has COVID-19 Changed Our PerceptionA/Prof. Takeshi Yoshida (Japan) |
10:00 – 10:30 ECCOR – Ready for Prime Time?Dr. Matthew Cove (Singapore) |
Symposium 5
| 11:00 – 12:30
Bronchoscopy and Interventional Techniques 1 |
11:00 – 11:20 Bronchoscopic Techniques To Target and Treat the Pulmonary NoduleProf. Calvin S. H. Ng (Hong Kong) |
11:20 – 11:40 Therapeutic Challenges in Malignant and Benign Airway StricturesProf. Hojoong Kim (Republic of Korea) |
11:40 – 12:00 Valves, Coils, Heat for COPD and Bronchial AsthmaProf. Pyng Lee (Singapore) |
12:00 – 12:20 Airway Stents Befitting of the FutureProf. Michael J. Simoff (USA) |
| 12:20 – 12:30
Q&A |
Symposium 6
| 11:00 – 12:30
Asthma 1 |
11:00 – 11:30 Optimizing Asthma Management in Primary CareA/Prof. Ngiap Chuan Tan (Singapore) |
11:30 – 12:00 Guideline and Policy ImplementationDr. Fanny Wai San Ko (Hong Kong) |
12:00 – 12:30 Challenges in Asthma Management in Low-Middle Income CountriesA/Prof. Phan Thu Phuong (Vietnam) |
Symposium 7
| 11:00 – 12:30
Interstitial Lung Disease 1 |
11:00 – 11:30 The Role of Genomics in ILD ManagementA/Prof. Joanne Ngeow (Singapore) |
11:30 – 12:00 Advances in ILD ImagingDr. Kyung Soo Lee (Republic of Korea) |
12:00 – 12:30 Biomarkers in ILDA/Prof. Lauren Troy (Australia) |
Symposium 8
| 11:00 – 12:30
Pulmonary Circulation 1 |
11:00 – 11:30 Pulmonary Hypertension in South East AsiaA/Prof. Edmund Lau (Australia) |
11:30 – 12:00 Building a Pulmonary Vascular Service Dr. Ruan Wen (Singapore) |
12:00 – 12:30 Group 3 Pulmonary Hypertension – Challenges and HopesAsst Prof. Sewa Duu Wen (Singapore) |
Symposium 9
| 13:30 – 15:00
Clinical Respiratory Medicine 1 |
| 13:30 – 13:50An Update on Current Guidelines on Diagnosis and Treatment of NTM Pulmonary Disease Prof. Charles L. Daley (USA) |
13:50 – 14:10 Environmental Risk of NTM Infection – Strategies for Prevention Prof. Doreen Addrizzo-Harris (USA) |
14:10 – 14:30 Targeting Energy of Life for Eradication of NTM Prof. Gerhard Grüber (Singapore) |
| 14:30 – 14:50Emergent Therapies for NTM Pulmonary Disease Prof. Charles L. Daley (USA) |
| 14:50 – 15:00
Q & A |
Symposium 10
| 13:30 – 15:00
Respiratory Neurobiology and Sleep 1 |
13:30 – 13:50 Phenotypic Assessment of OSA Beyond the AHIDr. Macy Mei-Sze Lui (Hong Kong) |
13:50 – 14:10 Pharmacotherapy for OSA Prof. Brendon Yee (Australia) |
14:10 – 14:30 Hypoglossal Nerve Stimulation in the Asian PopulationDr. Shaun Loh (Singapore) |
14:30 – 14:50 How Do We Deliver Personalised Therapy for OSADr. Sophie West (United Kingdom) |
| 14:50 – 15:00
Q&A |
Symposium 11
| 13:30 – 15:00
Respiratory Infections (non-Tuberculous) 1 |
13:30 – 14:00 How Fungi Affect the Diseased Lungs?Prof. Louis Chai (Singapore) |
14:00 – 14:30 Bringing Next Generation Sequencing (NGS) to the Bedside. Paving the Way Towards Precision Medicine Dr. Hanyu Qin (United Kingdom) |
14:30 – 15:00 Can We Manage the Critically Ill Better Using the Microbiome?Prof. Yuanlin Song (China) |
Symposium 12
| 13:30 – 15:00
Environmental and Occupational Health & Epidemiology 1 |
13:30 – 14:00 Recent Topics of Environmental and Occupational Exposure on Respiratory Health and DiseasesProf. Kazuhiro Yatera (Japan) |
14:00 – 14:30 Effect of Dust Exposure on Airway Diseases Prof. Woo Jin Kim (Republic of Korea) |
| 14:30 – 15:00Occupational Asthma: An Update Dr. Sundeep Salvi (India) |
Symposium 13
| 15:20 – 16:50
Critical Care Medicine 2 |
15:20 – 15:50 Evolution of Ventilation StrategiesProf. John J. Marini (USA) |
15:50 – 16:20 NIV Support in ICU Prof. Sunghoon Park (Republic of Korea) |
16:20 – 16:50 HFNCDr. Ser Hon Puah (Singapore) |
Symposium 14
| 15:20 – 16:50
COPD 2 |
15:20 – 15:50 Case 1Prof. Hao-Chien Wang (Taiwan) |
15:50 – 16:20 Case 2 Prof. Hye Yun Park (Republic of Korea) |
| 16:20 – 16:50Case 3 Adj A/Prof. Augustine Tee (Singapore) |
Symposium 15
| 15:20 – 16:50
Lung Cancer 2 |
15:20 – 15:50 Mx of Early NSCLCProf. Dr. Chong Kin Liam (Malaysia) |
15:50 – 16:20 Mx of Locally Adv Inoperable NSCLC Dr. Sita Andarini (Indonesia) |
16:20 – 16:50 Mx of Metastatic NSCLCDr. Chee Keong Toh (Singapore) |
Symposium 16
| 15:20 – 16:50
Cell and Molecular Biology 1 |
15:20 – 15:50 Novel Casein Kinase Inhibitor for Pulmonary FibrosisProf. Alastair Stewart (Australia) |
15:50 – 16:20 Development of A Labdane Diterpenoid Calcaratarin D for The Treatment of Asthma and Pulmonary Fibrosis Prof. W. S. Fred Wong (Singapore) |
16:20 – 16:50 Pharmacological Targets for Mycobacterial DiseasesA/Prof. Kevin Pethe (Singapore) |
Symposium 17
| 15:20 – 16:50
Respiratory Infections (non-Tuberculous) 2 |
15:20 – 15:50 COVID-19 ARDS – 2020 vs 2023, What Do We Know Now That We Should Have Known Then?Prof. Laurent Brochard (Canada) |
15:50 – 16:20 The Long Road to Recovery – The Journey to Understanding Long COVID A/Prof. Barnaby Young (Singapore) |
16:20 – 16:50 The Next Wave, Are We Ready for Future Pandemic?Prof. Dale Fisher (Singapore) |
Symposium 18
| 09:00 – 10:30
Interstitial Lung Disease 2 |
 Case 1: ILD that has Concurrent MalignancyDr. Yi Hern Tan (Singapore) |
 Case 2: ILD with Pulmonary Hypertension Dr. Ziqin Ng (Singapore) |
 Case 3: Unclassifiable ILD or ILD with Diagnostic DilemmaDr. Valencia Lim (Singapore) |
 Expert 1Prof. Athol Wells (United Kingdom) |
 Expert 2Dr. Yoshikazu Inoue (Japan) |
| Expert 3 Dr. Kyung Soo Lee (Republic of Korea) |
 Expert 4Asst Prof. Angela Takano (Singapore) |
Symposium 19
| 09:00 – 10:30
Bronchoscopy and Interventional Techniques 2 |
09:00 – 09:20 Thoracic Ultrasound for Respiratory FailureDr. Jansen Meng Kwang Koh (Singapore) |
09:20 – 09:40 Thoracoscopy in Empyema Dr. Imran Bin Mohamed Noor (Singapore) |
09:40 – 10:00 Thoracoscopy in PneumothoraxDr. Kim Hoong Yap (Singapore) |
10:00 – 10:20 Thoracoscopy, IPC, Pleurodesis for Malignant Pleural EffusionDr. Kiran Sharma (Singapore) |
| 10:20 – 10:30
Q&A |
Symposium 20
| 09:00 – 10:30
Asthma 2 |
09:00 – 09:30 Biologic SelectionProf. Philip Bardin (Australia) |
09:30 – 10:00 Defining Biologic Response and Asthma Remission Prof. Mi-Ae Kim (Republic of Korea) |
| 10:00 – 10:30Oral Corticosteroid Stewardship Dr. Fanny Wai San Ko (Hong Kong) |
Symposium 21
| 09:00 – 10:30
Clinical Allergy and Immunology 1 |
09:00 – 09:30 Selection of Biologic Therapy Based on Biomarkers of DiseaseA/Prof. Mariko Siyue Koh (Singapore) |
09:30 – 10:00 Fungal Sensitization as a Treatable Traits in Chronic Respiratory Disease A/Prof. Sanjay H. Chotirmall (Singapore) |
10:00 – 10:30 Vaccine Immunology – Lessons From COVID 19Dr. Adrian Kwok Wai Chan (Singapore) |
Symposium 22
| 11:00 – 12:30
Respiratory Structure and Function 1 |
11:00 – 11:30 Updates on Lung Function Test Interpretative StrategiesProf. Bruce Thompson (Australia) |
11:30 – 12:00 Artificial Intelligence in the Interpretation of Lung Function: Is This the Future? Prof. Marko Topalovic (Belgium) |
12:00 – 12:30 Reference Equations for Evaluation of Lung Function Tests and Its Practical Application in Asia-Pacific RegionDr. Geak Poh Tan (Singapore) |
Symposium 23
| 11:00 – 12:30
COPD 3 |
 ConProf. Wisia Wedzicha (United Kingdom) |
 Pro A/Prof. Thérèse Lapperre (Belgium) |
Symposium 24
| 11:00 – 12:30
Environmental and Occupational Health & Epidemiology 2 |
11:00 – 11:30 Biomass Exposure and Respiratory HealthProf. Jun-Pyo Myong (Republic of Korea) |
11:30 – 12:00 Novel Pollutants Affecting Respiratory Health: Air Microbiomes and MicroplasticsProf. John R. Balmes (USA) |
Symposium 25
| 11:00 – 12:30
Paediatric Lung Disease 1 |
11:00 – 11:30 The Early Origins of Childhood AsthmaProf. Peter Le-Souef (Australia) |
11:30 – 12:00 Approach and Management of Preschool Wheeze Prof. Sejal Saglani (United Kingdom) |
12:00 – 12:30 Sublingual Immunotherapy for Paediatric Respiratory DiseasesProf. Anne Goh (Singapore) |
Symposium 26
| 13:30 – 15:00
Clinical Respiratory Medicine 2 |
13:30 – 14:00 Establishing a Home Ventilation Service – Experience and Lessons LearntDr. Yeow Chan (Singapore) |
14:00 – 14:30 Caring for Patients on Chronic Mechanical Ventilation During the COVID Pandemic Ms. Tao Sun (Singapore) |
14:30 – 15:00 Respiratory Complications of Neuromuscular Disease and ManagementDr. Naveed Mustfa (United Kingdom) |
Symposium 27
| 13:30 – 15:00
Cell and Molecular Biology 2 |
13:30 – 14:00 Modulation of Iron Metabolism for the Treatment of Lung DiseaseProf. Jay Horvat (Australia) |
14:00 – 14:30 Innate and Adaptive Immune Response to Respiratory Virus Prof. Peter Wark (Australia) |
14:30 – 15:00 Isthmin 1 in Emphysema and Acute Lung InjuryA/Prof. Ruowen Ge (Singapore) |
Symposium 28
| 15:20 – 16:50
Clinical Respiratory Medicine 3 |
15:20 – 15:50 Breathlessness in Pleural Effusions – Physiology and ManagementProf. Y C Gary Lee (Australia) |
15:50 – 16:20 Refractory Transudative Pleural Effusions – Diagnosis and Management Dr. Anantham Devanand (Singapore) |
| 16:20 – 16:50Management of Persistent Air Leaks Asst Prof. Melvin Tay (Singapore) |
Symposium 29
| 15:20 – 16:50
Asthma 3 |
15:20 – 15:50 Addressing Asthma ComorbiditiesProf. Lee Kang Yun (Taiwan) |
15:50 – 16:20 Nonadherence in Asthma Dr. Amy Hai Yan Chan (New Zealand) |
16:20 – 16:50 ISAR – Real-World Evidence on Severe AsthmaProf. David B. Price (United Kingdom) |
Symposium 30
| 15:20 – 16:50
Interstitial Lung Disease 3 |
15:20 – 15:50 Diagnosis and Management of Drug Induced ILDDr. Su Ying Low (Singapore) |
| 15:50 – 16:20 Updates in Diagnosis and Management of Hypersensitivity Pneumonitis Dr. Yoshikazu Inoue (Japan) |
| 16:20 – 16:50Recent Advances in Management of Autoimmune Related ILD Prof. Athol Wells (United Kingdom) |
Symposium 31
| 15:20 – 16:50
Respiratory Neurobiology and Sleep 2 |
15:20 – 15:50 OSA COPD Overlap SyndromeDr. Ning-Hung Chen (Taiwan) |
15:50 – 16:20 OSA Asthma Overlap Syndrome A/Prof. Naricha Chirakalwasan (Thailand) |
16:20 – 16:50 Sleep Disorder and Cardiovascular DiseaseDr. Reena Mehra (USA) |
Symposium 32
| 15:20 – 16:50
Pulmonary Circulation 2 |
15:20 – 15:50 Pulmonary Embolism in Oncological PatientsDr. May Anne Cheong (Singapore) |
15:50 – 16:20 Evolving Spectrum of Treatment for CTEPHProf. Hiromi Matsubara (Japan) |
16:20 – 16:50 Building a Pulmonary Embolism Response TeamDr. Kristen Alexa Lee (Singapore) |
Symposium 33
| 15:20 – 16:50
Paediatric Lung Disease 2 |
15:20 – 15:50 Advances in Diagnostics of Paediatric SleepA/Prof. Arthur Teng (Australia) |
15:50 – 16:20 Genetics for the Paediatric Pulmonologists A/Prof. Denise Goh (Singapore) |
16:20 – 16:50 Advances in Paediatric Flexible BronchoscopyA/Prof. Mohammad Ashkan Moslehi (Iran) |
Symposium 34
| 09:30 – 11:00
Respiratory Infections (Non-Tuberculous) 3 |
09:30 – 10:00 Inhaled Therapies and Their Roles in the Vicious VortexProf. James D. Chalmers (United Kingdom) |
| 10:00 – 10:30 The Lung Microbiome – The Pulmonary Crystal Ball? A/Prof. Sanjay H. Chotirmall (Singapore) |
10:30 – 11:00 Suppressing the Fire – Can We Immunosuppress the Inflammatory Nature of Bronchiectasis?Prof. Yeon-Mok Oh (Republic of Korea) |
Symposium 35
| 09:30 – 11:00
Asthma 4 |
09:30 – 10:00 Asthma ImmunologyProf. Ian Pavord (United Kingdom) |
10:00 – 10:30 Asthma and the Environment – Allergens, Pollution and Microbes Prof. Jing Li (China) |
| 10:30 – 11:00Asthma Pathophysiology Prof. Ian Pavord (United Kingdom) |
Symposium 36
| 09:30 – 11:00
Clinical Allergy and Immunology 2 |
09:30 – 10:00 Allergen Immunotherapy – Using Biomarkers To Guide AIT SelectionDr. Takashi Iwanaga (Japan) |
10:00 – 10:30 Allergen Immunotherapy – Food Allergies Prof. Andreas L. Lopata (Australia) |
10:30 – 11:00 Allergen Immunotherapy – House Dust MitesA/Prof. Fook Tim Chew (Singapore) |
Symposium 37
| 09:30 – 11:00
Lung Cancer 3 |
09:30 – 10:00 Surgical Mx of MesotheliomaProf. John Kit Chung Tam (Singapore) |
10:00 – 10:30 Systemic Mx of Mesothelioma Dr. Puey Ling Chia (Singapore) |
| 10:30 – 11:00Mx of Small Cell Lung Cancer Asst Prof. Jens Samol (Singapore) |
Symposium 38
| 11:20 – 12:50
COPD 4 |
| 11:20 – 11:50COPD Lung Function Trajectories Prof. Wisia Wedzicha (United Kingdom) |
| 11:50 – 12:20 Precision Medicine in COPD A/Prof. Thérèse Lapperre (Belgium) |
| 12:20 – 12:50Year in Review: COPD Prof. Fernando J. Martinez (USA) |
Symposium 39
| 11:20 – 12:50
Tuberculosis 2 |
| 11:20 – 11:50TB Control in Shadow of the COVID Pandemic – Challenges for the Asia Pacific Region Dr. Chi Chiu Leung (Hong Kong) |
11:50 – 12:20 Update on Drug-Sensitive and MDR TB Treatment Regimens A/Prof. Cynthia Chee (Singapore) |
12:20 – 12:50 Whole Genome Sequencing for TB: From Bench to Bedside and BeyondAsst Prof. Rick Ong (Singapore) |
Symposium 40
| 11:20 – 12:50
Critical Care Medicine 3 |
| 11:20 – 11:50The Impact of the Latest ARDS Definition and ESICM ARDS Guidelines on Our Ventilatory Strategies Dr. Laurent Brochard (Canada) |
11:50 – 12:20 MV Discontinuation Practices and What Does the Evidence Tell Us Ms. Yvonne Cheng Fenelus (Singapore) |
| 12:20 – 12:50Patient-Ventilator Synchrony Dr. John J. Marini (USA) |
Symposium 41
| 11:20 – 12:50
Respiratory Structure and Function 2 |
11:20 – 11:50 Respiratory Structure and Physiology of the Aging LungProf. Gregory King (Australia) |
11:50 – 12:20 Post-COVID Impairment of Respiratory Structure & Function Dr. Xue Ning Choo (Singapore) |
12:20 – 12:50 The Future of Pulmonary Function TestingProf. Graham Hall (Australia) |
Symposium 42
| 13:30-15:00
Clinical Respiratory Medicine 4 |
13:30 – 13:50 Defining the Modern Pulmonary Rehabilitation (PR) – TelerehabilitationProf. Anne Holland (Australia) |
13:50 – 14:10 Nutritional Management in Chronic Obstructive Pulmonary Disease Ms. Chong Ying Lua (Singapore) |
14:10 – 14:30 An Update on Airway ClearanceDr. Arietta Spinou (United Kingdom) |
| 14:30 – 14:50
Interactive Discussion: How to set up a home-based and Telemedicine service – challenges and solutions
Prof. Anne Holland (Australia)
|
| 14:50 – 15:00 Q&A |
Oral Session 1
| 09:00 – 10:30
Oral Session 1 |
| 09:00 – 09:10
AO01-1 Long-term efficacy of dupilumab in patients with moderate-to-severe type 2 inflammation by age of asthma onset: LIBERTY ASTHMA TRAVERSE study |
| 09:10 – 09:20
AO01-2 Icariin treatment ameliorates macrophage activation in Th2-mediated asthma model by regulating the NF-MIF pathway |
| 09:20 – 09:30
AO01-3 Investigating the role of Isthmin-1 in allergic asthma: Implications for therapeutic interventions |
| 09:30 – 09:40
AO01-4 Diversity in airway responsiveness in bronchial asthma.A retrospective cohort study according to the Astograph method |
| 09:40 – 09:50
AO01-5 Homeostatic measure of insulin resistance is associated with future asthma exacerbations: a 1-year prospective cohort study |
| 09:50 – 10:00
AO01-6 A systematic review of the usefulness of as-required inhaled corticosteroid-agonist combination therapy for symptomatic-only patients with mild asthma |
| 10:00 – 10:10
AO01-7 Personalized treatment for mild asthma management: a solution from University Medical Center in Hochiminh, Vietnam |
Oral Session 2
| 09:00 – 10:30
Oral Session 2 |
| 09:00 – 09:10
AO02-1 Study protocol for the Australasian Malignant Pleural Effusion (AMPLE)-4 trial: a multicentre randomised study of topical antibiotics prophylaxis for infections of indwelling pleural catheters |
| 09:10 – 09:20
AO02-2 Predictive Risk Factors for Pneumothorax after Fluoroscopic Guided Transbronchial Lung Biopsy |
| 09:20 – 09:30
AO02-3 The Efficacy and Safety of Percutaneous Puncture Volume Reduction for Severe Pleural Adhesion Patients with Giant Emphysematous Bulla |
| 09:30 – 09:40
AO02-4 High Diagnostic Yield from Transbronchial Lung Biopsy by MonarchTM Robotic Bronchoscopy with cone-beam CT Guidance ; First Asian Experience |
| 09:40 – 09:50
AO02-5 Topical hemostatic agents for bleeding during elective flexible bronchoscopy: A Meta-analysis |
| 09:50 – 10:00
AO02-6 Explainable artificial intelligence (XAI) approach for age-dependent features in bronchoscopy images |
Oral Session 3
| 09:00 – 10:30
Oral Session 3 |
| 09:00 – 09:10
AO03-1 Estimated prevalence of fibrosing interstitial lung diseases based on serum biomarkers and chest radiographs interpreted by the deep-learning algorithm in a health checkup population |
| 09:10 – 09:20
AO03-2 Association between extent of reticulation and treatment response to pirfenidone in patients with idiopathic pulmonary fibrosis |
| 09:20 – 09:30
AO03-3 Explainable artificial intelligence model, MIXTURE, predicts equivalent prognostic value of UIP to worldwide expert pathologists |
| 09:30 – 09:40
AO03-4 Arachidonic acid metabolite, 17,18-epoxyeicosatetraenoic acid, attenuates profibrotic signaling in idiopathic pulmonary fibrosis |
| 09:40 – 09:50
AO03-5 Ablation of Ism1 exacerbates bleomycin-induced pulmonary fibrosis with enhanced cellular senescence and delayed fibrosis resolution |
| 09:50 – 10:00
AO03-6 Smoking Increases the Risk of Idiopathic Pulmonary Fibrosis by Reducing IGF1R Levels: a Mendelian Randomization and RNA-seq Study |
| 10:00 – 10:10
AO03-7 Alveolar type II specific deletion of FASN exacerbate pulmonary fibrosis |
Oral Session 4
| 09:00 – 10:30
Oral Session 4 |
| 09:00 – 09:10
AO04-1 Culin5/TRAF6/NF-VEGF-mediated endothelial dysfunction aggravates hypoxic pulmonary hypertension |
| 09:10 – 09:20
AO04-2 Diagnostic value of Padua Prediction Score in medical patients with suspected peripherally inserted central catheter related upper extremity venous thrombosis |
| 09:20 – 09:30
AO04-3 Persistent Right Ventricular Dysfunction and Long-term Changes of Right Heart Function after Acute Pulmonary Embolism: Systematic Review and Meta-analysis |
| 09:30 – 09:40
AO04-4 Effect of pulmonary vasodilators on pulmonary hypertension associated with connective tissue disease related interstitial pneumonia |
| 09:40 – 09:50
AO04-5 Protective effect of early Anticoagulation for Renal Function in Normotensive Pulmonary Embolism Patients with Right Ventricular Dysfunction |
| 09:50 – 10:00
AO04-6 Long-term survival of systemic sclerosis with pulmonary arterial hypertension patients |
Oral Session 5
| 11:00 – 12:30
Oral Session 5 |
| 11:00 – 11:10
AO05-1 High-sensitivity C-reactive protein level in in stable state bronchiectasis predicts exacerbation risk |
| 11:10 – 11:20
AO05-2 Burden of disease and clinical outcomes of patients referred to Refractory Chronic Cough Clinic |
| 11:20 – 11:30
AO05-3 Spirometry pattern of restrictive and mixed ventilatory defect and risk of exacerbation in patients with bronchiectasis: a prospective KMBARC cohort study |
| 11:30 – 11:40
AO05-4 Non-cystic Fibrosis Bronchiectasis Characteristics in Taiwan: data from the Taiwan Bronchiectasis Registry (TBARC) |
| 11:40 – 11:50
AO05-5 High dose oral N- Acetylcysteine in the treatment of bronchiectasis: A double-blind, randomised pilot study assessing anti-inflammatory and clinical outcomes in adults |
| 11:50 – 12:00
AO05-6 Bronchial lavage fluid from patients with clinically non-significant and significant bronchiectasis |
Oral Session 6
| 11:00 – 12:30
Oral Session 6 |
| 11:00 – 11:10
AO06-1 Sleep-wake Patterns in Hong Kong Chinese Adolescents |
| 11:10 – 11:20
AO06-2 Prevalence and predictors of habitual snoring in Hong Kong Chinese Adolescents |
| 11:20 – 11:30
AO06-3 A comparison of sleep quality, sleep duration, and excessive daytime sleepiness among medical students |
| 11:30 – 11:40
AO06-4 Factors associated with acceptance of positive airway pressure (PAP) treatment among obstructive sleep apnoea (OSA) patients in Malaysia |
| 11:40 – 11:50
AO06-5 Endotypic traits of supine-predominant obstructive sleep apnea |
| 11:50 – 12:00
AO06-6 The Effectiveness of Educational Programs on CPAP Adherence among Patients with Obstructive Sleep Apnea (OSA) at Phramongkutklao Hospital |
| 12:00 – 12:10
AO06-7 A case report of severe obstructive sleep apnea leading to young hypertension complicated with intracranial hemorrhage |
Oral Session 7
| 11:00 – 12:30
Oral Session 7 |
| 11:00 – 11:10
AO07-1 Lung Opacity Score of COVID-19 Patients and its Association withChest CT Scan Findings and Functional Capacity9 to 18 months after discharge |
| 11:10 – 11:20
AO07-2 Abstract Withdrawn |
| 11:20 – 11:30
AO07-3 Retrospective clinical study of the efficacy of celecoxib, a COX-2 inhibitor, in the treatment of COVID-19 pneumonia |
| 11:30 – 11:40
AO07-4 The outcome of long-course oral corticosteroids in COVID-19-related diffuse interstitial lung abnormalities |
| 11:40 – 11:50
AO07-5 The Clinical Outcome of Patients with Post Covid-19 Condition Who Underwent Pulmonary Telerehabilitation in Lung Center of the Philippines |
| 11:50 – 12:00
AO07-6 Evaluation of Potential Cardiovascular Adverse Events of Remdesivir and Favipiravir in COVID-19 Patients |
| 12:00 – 12:10
AO07-7 The prevalence of Long COVID, associating factors, and the holistic outcomes in COVID-19 patients |
| 12:10 – 12:20
AO07-8 Anticoagulant therapy in adult with COVID-19：a meta-analysis of randomized controlled trial |
| 12:20 – 12:30
AO07-9 Similarities and differences between COVID-19-induced and typical ARDS at the time of hospital admission |
Oral Session 8
| 11:00 – 12:30
Oral Session 8 |
| 11:00 – 11:10
AO08-1 Astaxanth ininhibits CSE-induced oxidative stress in BEAS-2B cells via the Nrf2/HO-1 pathway thereby suppressing ferroptosis |
| 11:10 – 11:20
AO08-2 KGF-2-induced proliferation of alveolar macrophages ameliorates acute lung injury |
| 11:20 – 11:30
AO08-3 Exploring the crucial role of signal regulatory protein in airway epithelial cells |
| 11:30 – 11:40
AO08-4 Cellular and molecular analysis of T cell-dependent steroid-resistant asthma model |
| 11:40 – 11:50
AO08-5 The role of OLFML3 in regulating macrophage inflammatory immunity |
| 11:50 – 12:00
AO08-6 Differential cord blood responses to RSV between preterm and term infants |
| 12:00 – 12:10
AO08-7 Association between Sputum Myeloperoxidase Concentration and Bronchiectasis Status |
| 12:10 – 12:20
AO08-8 Reduction in ventilation-enhanced diaphragmatic muscle fibrosis through the phosphoinositide 3-kinase-r in a murine bleomycin-induced acute lung injury model |
Oral Session 9
| 13:30 – 15:00
Oral Session 9 |
| 13:30 – 13:40
AO09-1 METTL3-mediated m6A modification of FSP1 mRNA is involved in COPD emphysema by inducing ferroptosis |
| 13:40 – 13:50
AO09-2 MicroRNA Let-7 induces M2 macrophage polarization in COPD emphysema through the IL-6/STAT3 pathway |
| 13:50 – 14:00
AO09-3 Effect of application of Transcutaneous Electrical Nerve Stimulation on acupoints (Acu-TENS) on cigarette smoke-induced COPD-like animal model |
| 14:00 – 14:10
AO09-4 Correlation of Fat-to-Muscle Mass Ratio Using the Bioimpedance Analyzer with VO2 Max Among COPD and PRISm Patients |
| 14:10 – 14:20
AO09-5 Chest Wall Mobilization on Thoracic Excursion and Respiratory Function in relation to Respiratory Efficiency and Functional Capacity in Severe COPD: A Randomized Controlled Trial |
| 14:20 – 14:30
AO09-6 Physical frailty as a surrogate for insufficient peak inspiratory flow in patients with chronic obstructive pulmonary disease |
| 14:30 – 14:40
AO09-7 Ultrasound evaluation of parasternal intercostal muscle and diaphragm in patients with stable chronic obstructive pulmonary disease |
| 14:40 – 14:50
AO09-8 Association of non-obstructive dyspnea with all-cause mortality and incident COPD: a systematic literature review and meta-analysis |
| 14:50 – 15:00
AO09-9 Inter-relationships among impaired diffusing capacity and small airways dysfunction in ECOPD cohort: a population-based prospective cohort study |
Oral Session 10
| 13:30 – 15:00
Oral Session 10 |
| 13:30 – 13:40
AO10-1 Pathogenic characteristics of multidrug-resistant strains among retreated tuberculosis and the host response |
| 13:40 – 13:50
AO10-2 Application of High-Throughput Metagenomic Sequencing in Tuberculosis Diagnosis: Platform Comparison and Diagnostic Potential |
| 13:50 – 14:00
AO10-3 Intertangled factors of drug resistance, compensatory evolution and virulence: impact on Mycobacterium tuberculosis transmission in high-burden country |
| 14:00 – 14:10
AO10-4 A case of linezolid- and bedaquline-resistant tuberculosis transmission event revealed by genomic sequencing and genotyping |
| 14:10 – 14:20
AO10-5 The Correlation between Genetic Polymorphisms NAT2 and SLCO1B1 with Drug Induced Hepatotoxicity Caused Isoniazid and Rifampicin in Tuberculosis Patients |
| 14:20 – 14:30
AO10-6 Genotyping and Virulence Assessment of Mycobacterium Tuberculosis Strains in Indonesia |
Oral Session 11
| 13:30 – 15:00
Oral Session 11 |
| 13:30 – 13:40
AO11-1 Sublobar Resection Versus Lobectomy for Stage IA Non-Small-Cell Lung Cancer ≤2cm: A Systematic Review and Patient-Level Meta-Analysis |
| 13:40 – 13:50
AO11-2 Clinical implication of preoperative administration of ninjinyoeito to patients planning lung cancer surgery |
| 13:50 – 14:00
AO11-3 Treatment and survival outcomes for indigenous Australians within the Victorian Lung Cancer Registry: A retrospective cross-sectional cohort study |
| 14:00 – 14:10
AO11-4 Incidental findings from lung cancer screening with low-dose computed tomography in Australia and Canada; early results from the International Lung Screen Trial cohort |
| 14:10 – 14:20
AO11-5 Coronary artery calcification detected on low-dose computed tomography in high-risk participants of a lung cancer screening program; early results an Australian International Lung Screen Trial (ILST) cohort |
| 14:20 – 14:30
AO11-6 A retrospective audit of lung nodules with validation of the Brock tool in a Singaporean cohort |
| 14:30 – 14:40
AO11-7 Transbronchial cryobiopsy using a 1.1mm diameter cryoprobe for next-generation sequencing in lung cancer |
| 14:40 – 14:50
AO11-8 5-HT suppresses tumor progression and facilitates the efficacy of combination immunotherapy in depressed lung cancer mice |
Oral Session 12
| 13:30 – 15:00
Oral Session 12 |
| 13:30 – 13:40
AO12-1 Handgrip strength as a predictor of independent walking upon discharge in critically ill adults: a prospective study in advanced emergency and critical care center |
| 13:40 – 13:50
AO12-2 Effectiveness of ROX Index and Modified ROX Index in Predicting High-Flow Nasal Cannula Therapy Failure in Patients After Extubation: A Retrospective Study |
| 13:50 – 14:00
AO12-3 Association between plasma endothelial glycocalyx markers and the prognosis of ARDS |
| 14:00 – 14:10
AO12-4 Culture-Negative Sepsis and Culture-Positive Sepsis: A Prospective Nationwide Multicenter Cohort Study |
| 14:10 – 14:20
AO12-5 Protective Role of Metrnl in Host Immunity Defense during Sepsis by Promoting Macrophage Recruitment and Modulating Treg/Th17 Immune Cell Balance |
| 14:20 – 14:30
AO12-6 Comparing NEWS, SIRS, and qSOFA as predictor scores for mortality and length of hospitalization in pneumonia with sepsis |
Oral Session 13
| 15:20 – 16:50
Oral Session 13 |
| 15:20 – 15:30
AO13-1 Pulmonary function, functional capacity, respiratory, and body muscle strength after severe to critical ill COVID-19: a long-term study |
| 15:30 – 15:40
AO13-2 Absolute monocyte count as an alternative marker in COVID-19 severity: a perspective from a national tertiary hospital |
| 15:40 – 15:50
AO13-3 Mysterious voice box with resistant stridor ; A dilemma in diagnosis |
| 15:50 – 16:00
AO13-4 EVALI and cardiac dysfunction in a young Filipino male |
| 16:00 – 16:10
AO13-5 Clinical outcome and patent characteristics of community acquired pneumonia in a secondary care hospital in central Sri Lanka; are severity indexes and scores universally applicable? |
| 16:10 – 16:20
AO13-6 A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects |
| 16:20 – 16:30
AO13-7 An unusual presentation of a known entity; The great masquerader |
Oral Session 14
| 15:20 – 16:50
Oral Session 14 |
| 15:20 – 15:30
AO14-1 Increased risk of new-onset interstitial lung disease after COVID-19 infection: A nationwide population-based cohort Study |
| 15:30 – 15:40
AO14-2 Risk factors and associations of pulmonary hypertension in interstitial lung disease: a systematic review |
| 15:40 – 15:50
AO14-3 Reliability of visual HRCT score in determining the extent of fibrosis in patients with idiopathic pulmonary fibrosis |
| 15:50 – 16:00
AO14-4 The Concept of UIP Bucket: Usual Interstitial Pneumonia (UIP) as the Core Histology of Progressive Pulmonary Fibrosis (PPF) Across Different Etiologies |
| 16:00 – 16:10
AO14-5 The Initial Impact of the First Established Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Interstitial Lung Diseases in Vietnam |
| 16:10 – 16:20
AO14-6 Efficacy and safety of nintedanib in patients with early-stage idiopathic pulmonary fibrosis: A prospective, multicenter observational cohort study in Kyushu and Okinawa, Japan |
Oral Session 15
| 09:00 – 10:30
Oral Session 15 |
| 09:00 – 09:10
AO15-1 Evaluation of a Multidisciplinary Telehealth Program for COPD Patients: Insights from a Singapore Tertiary Hospital Experience |
| 09:10 – 09:20
AO15-2 Exacerbations and annualised change in COPD symptoms in patients with airways colonised with potentially pathogenic organisms when stable |
| 09:20 – 09:30
AO15-3 Influenza and Pneumococcal Vaccination Rates and Associated Factors in Patients Hospitalized with Acute Exacerbations of COPD in China: Findings from the Real World Data |
| 09:30 – 09:40
AO15-4 Variability of blood eosinophil count at stable-state in predicting exacerbation risk of chronic obstructive pulmonary disease |
| 09:40 – 09:50
AO15-5 Effects of chronic obstructive pulmonary disease and metabolic syndrome on incident cardiovascular disease and mortality |
| 09:50 – 10:00
AO15-6 Tiotropium Reduces Clinically Important Deterioration in Patients with Mild-to-moderate Chronic Obstructive Pulmonary Disease |
Oral Session 16
| 09:00 – 10:30
Oral Session 16 |
| 09:00 – 09:10
AO16-1 Sleep disordered breathing in community aging population ; a preliminary report |
| 09:10 – 09:20
AO16-2 Magic Ring; Triage Service: Integration of Artificial Intelligence into Multidisciplinary Management of Obstructive Sleep Apnea and Insomnia |
| 09:20 – 09:30
AO16-3 Reliability of 3% oxygen desaturation index (ODI-3%) derived from level 1 polysomnography (PSG) data and STOP-BANG questionnaire in identifying obstructive sleep apnoea (OSA) in adults |
| 09:30 – 09:40
AO16-4 Pediatric Obstructive Sleep Apnea and Recurrent Laryngotracheobronchitis in a 2-year-old male: A Case Report |
| 09:40 – 09:50
AO16-5 Diaphragm pacing for acquired central hypoventilation following brain tumour resection can facilitate safe discharge home |
| 09:50 – 10:00
AO16-6 Effects of chronic beedi smoking on sleep quality |
| 10:00 – 10:10
AO16-7 Complete Resolution of Syncope after CPAP therapy in a Patient with Moderate Obstructive Sleep Apnea: A Case Report |
Oral Session 17
| 09:00 – 10:30
Oral Session 17 |
| 09:00 – 09:10
AO17-1 Malignant mesothelioma presenting as a breast mass – A rare case report |
| 09:10 – 09:20
AO17-2 Meigs’ syndrome: a rare cause of the recurrent pleural effusion |
| 09:20 – 09:30
AO17-3 Beyond skin rash – an unusual case of herpes zoster causing dyspnoea |
| 09:30 – 09:40
AO17-4 Evaluation of the efficacy of oral Bacterial Lysates in patients with high-risk lung nodules detected by CT screening: a retrospective study |
| 09:40 – 09:50
AO17-5 William campbell plus syndrome: A novel disease entity or an unusual presentation of a rare disorder? |
| 09:50 – 10:00
AO17-6 Breathing Trouble: A case of bronchopulmonary leukemic infiltrates in Chronic Lymphocytic Leukemia |
| 10:00 – 10:10
AO17-7 Thoracic endometriosis: Does an after-menstruation thoracostomy still provide optimal visualization while reducing the recurrence rate of catamenial pneumothorax? |
Oral Session 18
| 09:00 – 10:30
Oral Session 18 |
| 09:00 – 09:10
AO18-1 Applicability of the Global Lung Function Initiative (GLI)-2012 equations to Hong Kong Chinese children |
| 09:10 – 09:20
AO18-2 Clinical Features and Treatment of Congenital Central Hypoventilation Syndrome: a Single-Center Experience |
| 09:20 – 09:30
AO18-3 Respiratory sequelae after COVID-19 infection in Thai healthy children |
| 09:30 – 09:40
AO18-4 Pulmonary dysfunction among adolescents in Vietnam: using ERS/ATS 2021 guidelines for lung function interpretation |
| 09:40 – 09:50
AO18-5 Clinical determinants for state-trait anxiety inventory of the parents of children with respiratory problems |
| 09:50 – 10:00
AO18-6 The distribution of human adenovirus genotype detected from children with community acquired pneumonia in Ho Chi Minh city in 2019 and 2020 |
| 10:00 – 10:10
AO18-7 Mind the Gap: Identifying Research Gaps from Systematic Reviews of Pneumonia Treatment in Children |
Oral Session 19
| 11:00 – 12:30
Oral Session 19 |
| 11:00 – 11:10
AO19-1 Current status of Influenza A and B virus infection among adults and children |
| 11:10 – 11:20
AO19-2 Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients |
| 11:20 – 11:30
AO19-3 Chronic pulmonary aspergillosis in newly diagnosed pulmonary tuberculosis patients: A prospective cohort study of 252 patients from beginning to end of therapy |
| 11:30 – 11:40
AO19-4 The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China |
| 11:40 – 11:50
AO19-5 Alteplase dose assessment for pleural infection therapy (ADAPT) study-3: A starting intrapleural dose of 1mg alteplase |
| 11:50 – 12:00
AO19-6 Clinical values of metagenomic next-generation sequencing in patients with severe pneumonia |
| 12:00 – 12:10
AO19-7 Safety and immunogenicity of the respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in Asian older adults (≥60 years of age) |
| 12:10 – 12:20
AO19-8 The NEWS2 score is a useful predictor of severity in Community-Acquired Pneumonia in Singapore |
Oral Session 20
| 11:00 – 12:30
Oral Session 20 |
| 11:00 – 11:10
AO20-1 Earlier mechanical ventilation is associated with lower mortality in patients with sepsis |
| 11:10 – 11:20
AO20-2 Evaluation of patients with severe COVID-19 using lung ultrasound |
| 11:20 – 11:30
AO20-3 dCROX and ROX indices predict clinical outcomes in patients with COVID-19 pneumonia treated with high-flow nasal cannula oxygen therapy |
| 11:30 – 11:40
AO20-4 Effects of delayed prone position in acute respiratory distress syndrome |
| 11:40 – 11:50
AO20-5 Incidence of post-intensive care syndrome in critical COVID-19 patients who survived to hospital discharge in a university hospital |
Oral Session 21
| 11:00 – 12:30
Oral Session 21 |
| 11:00 – 11:10
AO21-1 Asthma and susceptibility to COVID-19 in Australian children during alpha, delta and omicron waves |
| 11:10 – 11:20
AO21-2 Safer use of short-acting beta-agonists: providing information to better perceive and manage risk ; a qualitative study |
| 11:20 – 11:30
AO21-3 Reduced asthma exacerbations in adult patients treated with bronchial thermoplasty: a retrospective nationwide database study |
| 11:30 – 11:40
AO21-4 Co-Designing Asthma Health Literacy with Culturally and Linguistically Diverse (CALD) Communities |
| 11:40 – 11:50
AO21-5 Clinical Characteristics of Refractory Allergic Bronchopulmonary Aspergillosis |
| 11:50 – 12:00
AO21-6 Analysis of clinical characteristics of subacute cough patients with allergic rhinitis |
Oral Session 22
| 11:00 – 12:30
Oral Session 22 |
| 11:00 – 11:10
AO22-1 Obesity-related systemic oxidative stress leads to steroid resistance in obese asthmatic patients |
| 11:10 – 11:20
AO22-2 The effect of inactivated virus SARS-CoV-2 vaccine to induced specific responses CD4+ T-cells, CD8+ T-cells, and neutralizing antibodies after completing two doses of immunization |
| 11:20 – 11:30
AO22-3 The role of invariant natural killer T cells in steroid-resistant airway inflammation induced by chitin |
| 11:30 – 11:40
AO22-4 Unraveling the Immunophenotypes of Pneumonitis in Cancer Treatment Through Mass Cytometry Exploration |
| 11:40 – 11:50
AO22-5 Assessing adherence barriers using the adherence starts with knowledge 20 questionnaire in patients with asthma |
| 11:50 – 12:00
AO22-6 Reported Penicillin Allergy and Its Effect on Mortality in Patients with Bacterial Pneumonia |
Oral Session 23
| 13:30 – 15:00
Oral Session 23 |
| 13:30 – 13:40
AO23-1 Validation of Global Lung Initiative (GLI) and local reference equation in Healthy Adult in Singapore |
| 13:40 – 13:50
AO23-2 Respiratory assessment of chronic lung disease patients using electrical impedance tomography, spirometry, and computational tomography |
| 13:50 – 14:00
AO23-3 The Utility of Forced Oscillation Technique in the Assessment of Obstructive Lung Disease among Adult Patients |
| 14:00 – 14:10
AO23-4 Characteristics of cardiopulmonary exercise testing in patients with interstitial pneumonia with autoimmune features |
| 14:10 – 14:20
AO23-5 Clinical Characteristics and prognosis in Patients with Bronchiectasis Depending on Bronchodilator Response in Korean Bronchiectasis Cohort |
| 14:20 – 14:30
AO23-6 Emergency department-to-outpatient conservative management of primary spontaneous pneumothorax – a single centre experience |
Oral Session 24
| 13:30 – 15:00
Oral Session 24 |
| 13:30 – 13:40
AO24-1 Identifying the prevalence of severe asthma in a Malaysian tertiary hospital |
| 13:40 – 13:50
AO24-2 Impact of treatable traits and treatment choices on reliever/rescue medication use |
| 13:50 – 14:00
AO24-3 Associations between earlier life risk factor profiles and all-cause and cause-specific mortality in the seventh decade: Tasmanian Longitudinal Health Study |
| 14:00 – 14:10
AO24-4 Asynchronous digital health interventions (aDHI) for reviewing asthma: a mixed-methods systematic review |
| 14:10 – 14:20
AO24-5 Risk Prediction Models of Exacerbations in Adults with Asthma: an Updated Systematic Review |
| 14:20 – 14:30
AO24-6 Comparison of adult asthma receiving primary vs. specialist healthcare in Singapore ; Data from SingHealth-Duke-NUS- GSK COPD and Asthma Real World Evidence (SDG-CARE) Asthma Registry |
| 14:30 – 14:40
AO24-7 Application of Bayesian network in investigating risk factors and treatment interactions in severe asthma patients |
Oral Session 25
| 13:30 – 15:00
Oral Session 25 |
| 13:30 – 13:40
AO25-1 Lung destruction and abnormal proper esophageal artery contribute to a higher recurrence rate of haemoptysis in post-tuberculosis bronchiectasis compared to idiopathic bronchiectasis |
| 13:40 – 13:50
AO25-2 Factors associated with depression among elderly tuberculosis patients: a prospective multicenter cohort study |
| 13:50 – 14:00
AO25-3 Impact of COVID-19 epidemic on active case-finding of tuberculosis in Japan |
| 14:00 – 14:10
AO25-4 Role of Sequential Technique of sample collection in Microbiological Diagnosis of Pulmonary Tuberculosis: A Real-world Study |
| 14:10 – 14:20
AO25-5 Factors influencing illness perception of latent tuberculosis infection: a prospective multicenter cohort study |
| 14:20 – 14:30
AO25-6 Tuberculosis treatment-outcome among Covid-19 patients admitted at the Lung Center of the Philippines |
| 14:30 – 14:40
AO25-7 The usefulness of cell free DNA in pleural effusion for diagnosing tuberculous pleurisy |
Oral Session 26
| 13:30 – 15:00
Oral Session 26 |
| 13:30 – 13:40
AO26-1 Developing a precision-cut lung slice model to study the initiation of silicosis |
| 13:40 – 13:50
AO26-2 Longitudinal Transition Trajectories of the Preserved Ratio Impaired Spirometry and Long-term Cardiovascular Outcomes: the PURE-China Study |
| 13:50 – 14:00
AO26-3 Impact of household air pollution on the health of women living in urban slums |
| 14:00 – 14:10
AO26-4 The effects of PM 2.5 and particle constituents on overall, cardiovascular and respiratory mortality in Seoul |
| 14:10 – 14:20
AO26-5 Frequency of respiratory symptoms among workers of tobacco processing factory in Bangladesh |
| 14:20 – 14:30
AO26-6 A study of heavy metal levels in the blood of small-scale gold miners |
| 14:30 – 14:40
AO26-7 Alveolar macrophage carbon as an internal marker for traffic-related air pollution exposure in children |
Oral Session 27
| 15:20 – 16:50
Oral Session 27 |
| 15:20 – 15:30
AO27-1 Sputum microbiota composition can predict the disease progression in patients with nontuberculous mycobacterium lung disease |
| 15:30 – 15:40
AO27-2 The role of exosome in nontuberculous mycobacterial lung disease |
| 15:40 – 15:50
AO27-3 Clinical characteristics of bronchiectasis patients with Mycobacterium abscessus infection ; a single centre study |
| 15:50 – 16:00
AO27-4 Natural History of Radiological Pleuroparenchymal Fibroelastosis Patterns in Nontuberculous Mycobacterial Pulmonary Disease: A Multicenter Retrospective Study in Japan |
| 16:00 – 16:10
AO27-5 Effectiveness of clofazimine-containing regimen in the treatment of Mycobacterium avium complex pulmonary disease |
| 16:10 – 16:20
AO27-6 The clinical characteristics of type 2 inflammation in patients with bronchiectasis in East Asia population |
| 16:20 – 16:30
AO27-7 Pseudomonas aeruginosa Phenotypes Associated with Radiographic Severity in Adult Patients with Non-Cystic Fibrosis Bronchiectasis |
| 16:30 – 16:40
AO27-8 More exacerbations of bronchiectasis after recovery from mild-to-moderate COVID-19 in patients with non-cystic fibrosis bronchiectasis |
| 16:40 – 16:50
AO27-9 Phosphoglycerate dehydrogenase regulates the pro-inflammatory response of alveolar macrophages in Pseudomonas aeruginosa lung infection by modulating the PPAR-NF-KB signalling pathway |
Oral Session 28
| 15:20 – 16:50
Oral Session 28 |
| 15:20 – 15:30
AO28-1 Exploring Systemic Immune-Inflammation Index as a Potential Predictor of Platinum-Based Chemotherapy Response in Advanced Stage Non-Small Cell Lung Cancer |
| 15:30 – 15:40
AO28-2 Almonertinib plus olaparib treat epidermal growth factor receptor 21 exon V834L with ARID1A Q171 co-mutation in a patient with non-small cell lung cancer |
| 15:40 – 15:50
AO28-3 Comparative Effects of Afatinib and Gefitinib as First-Line Treatment in Patients with Advanced Stage Non-Small Cell Lung Cancer with Common Egfr Mutations: Real-World Data on PFS |
| 15:50 – 16:00
AO28-4 Comparison of DNA methylation profiling between primary and metastatic lesions in autopsy cases of untreated lung adenocarcinoma |
| 16:00 – 16:10
AO28-5 Peripheral blood markers associated with treatment response and survival in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy |
| 16:10 – 16:20
AO28-6 Mechanism of afatinib resistance in Non-small Cell Lung Cancer patients with non-classical EGFR mutations: A multicenter study |
| 16:20 – 16:30
AO28-7 Development of novel tryptophan-based antibody-drug conjugates for EGFR-expressing lung cancer |
| 16:30 – 16:40
AO28-8 Stress and depression levels in lung cancer patients undergoing chemotherapy at dr. Zainoel Abidin Hospital Banda Aceh, Indonesia |
Oral Session 29
| 09:30 – 11:00
Oral Session 29 |
| 09:30 – 09:40
AO29-1 Estimating the effects of physical activity and physical fitness on chronic obstructive pulmonary disease development using graphical causal models: a UK Biobank study |
| 09:40 – 09:50
AO29-2 Hybrid pulmonary rehabilitation for patients with COPD: an equivalence trial |
| 09:50 – 10:00
AO29-3 Using Mobile Health Technology to Deliver a home-based pulmonary rehabilitation program for COPD Patients: A pilot study |
| 10:00 – 10:10
AO29-4 Effect of Virtual Pulmonary Rehabilitation among Patients with Chronic Obstructive Pulmonary Disease |
| 10:10 – 10:20
AO29-5 Dietary phytochemicals and COPD: therapeutic effects of tea and curry consumption observed in the Singapore Longitudinal Ageing Studies |
| 10:20 – 10:30
AO29-6 The association of long-term breathlessness with disability: a population-based, cross-sectional study |
| 10:30 – 10:40
AO29-7 Impaired Exercise Tolerance in Patients with Mild-to-moderate Chronic Obstructive Pulmonary Disease |
| 10:40 – 10:50
AO29-8 Development of a Scoring System to Predict Suboptimal Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease |
Oral Session 30
| 09:30 – 11:00
Oral Session 30 |
| 09:30 – 09:40
AO30-1 Clinical Outcomes of Pulmonary Rehabilitation Program Among COVID-19 Patients Within One Year of Recovery |
| 09:40 – 09:50
AO30-2 Pulmonary tele-rehabilitation program (tele-PRP) improves physical and functional health in patients having chronic respiratory diseases |
| 09:50 – 10:00
AO30-3 Developing an ethical framework for consideration of home invasive mechanical ventilation (HIMV) in adults |
| 10:00 – 10:10
AO30-4 The effects of smoking cessation therapy on pulmonary function and health-related quality of life in asthma patients |
| 10:10 – 10:20
AO30-5 Pulmonary function and six-minute-walk test in patients after recovery from COVID-19 pneumonia |
| 10:20 – 10:30
AO30-6 Effect of Neck Stabilization Exercises on Respiratory Function of Community-Dwelling Elderly Stroke Patients with Hemiplegia. A Randomized Control Trial |
Oral Session 31
| 09:30 – 11:00
Oral Session 31 |
| 09:30 – 09:40
AO31-1 Comparison of the specimen quality of endobronchial ultrasound-guided intranodal forceps biopsy using a miniforceps versus standard-sized forceps for advanced-stage lung cancer: a prospective study |
| 09:40 – 09:50
AO31-2 A Bloody Pleural Effusion |
| 09:50 – 10:00
AO31-3 A prospective study comparing the diagnostic rates and safety of 22G and 25G needles in endobronchial ultrasound-guided transbronchial needle aspiration |
| 10:00 – 10:10
AO31-4 Use of rapid on-site cytology does not enhance diagnostic rates with endobronchial ultrasound transbronchial needle aspiration |
| 10:10 – 10:20
AO31-5 The diagnostic yield of lymphoma and sarcodiosis using Endobronchial ultrasound-guided transbronchial mini forceps biopsy |
| 10:20 – 10:30
AO31-6 Diagnostic accuracy of the cryo 1.1mm probe peripheral biopsy; with or without guide sheathe |
| 10:30 – 10:40
AO31-7 Modification of radial probe endobronchial ultrasound technique as a diagnostic tool for peripheral pulmonary lesions without guide sheath/fluoroscopy |
| 10:40 – 10:50
AO31-8 Hypoxemia during bronchoscopy and the risk factors related |
Oral Session 32
| 11:20 – 12:50
Oral Session 32 |
| 11:20 – 11:30
AO32-1 Hypoxia signaling triggered neuro cell death after direct brain infection by SARS-CoV2 in Syn1-hACE2-Tg mice |
| 11:30 – 11:40
AO32-2 Changes in the Behaviors Among Family Members of Patients with Severe Pneumonia |
| 11:40 – 11:50
AO32-3 Clinical characteristics, outcome and factors associated with mortality of Pulmonary Mucormycosis |
| 11:50 – 12:00
AO32-4 Activation of 7 nicotinic acetylcholine receptor in AT2 promotes alveolar regeneration through WNT7B signaling in acute lung injury |
| 12:00 – 12:10
AO32-5 Test characteristics of FDA-approved pneumonia PCR panel compared to respiratory cultures and its impact on clinical outcomes |
| 12:10 – 12:20
AO32-6 Clinical significance of IL-6 in severe and critical COVID-19 patients |
